Paul B. Chapman, M.D.

Medical Oncology

Locations and Appointments

Insurances Accepted

Please contact the doctor's office to verify that your insurance is accepted.

*Indicates this doctor is no longer accepting new patients with this insurance plan.

  • HMO
  • Medicare
  • PPO
  • CHP
  • Blue Access
  • Blue Connection
  • EPO
  • HMO
  • Mediblue (Senior)
  • PPO
  • CBP
  • Medicaid
  • Medicare
  • Freedom
  • Liberty
  • Medicare Advantage
  • Metro/Core/Charter
  • Community Plan
  • Medicare
  • HMO
  • Medicare
Personal Statement

I have spent my career focused on one goal: to develop new and improved treatments for melanoma and bring these therapies to patients. When patients are faced with the need to make decisions about treatment options, it can feel complicated and stressful. I think it’s important to explain the various options that are available to my patients and provide them with my recommendations based on over 35 years of experience treating people with melanoma. It is personally gratifying to me that during this time, the science has advanced significantly and treatment outcomes have improved dramatically. While this progress has been significant, my colleagues and I remain hard at work everyday to improve outcomes even further.

Biographical Info

Paul Chapman, MD is currently the Chief Medical Research Officer for the Meyer Cancer Center at Weill Cornell Medicine and NewYork-Presbyterian Hospital. Dr. Chapman received his M.D. degree from Weill Cornell Medical College in 1981 and trained in internal medicine as an intern and resident at the University of Chicago Hospitals and Clinics from 1981-1984. After that, he returned to New York as a medical oncology Fellow at Memorial Sloan Kettering Cancer where he focused on immunotherapy of melanoma in the laboratory of Dr. Alan Houghton. He joined the faculty of Memorial Sloan Kettering Cancer Center (MSKCC) in 1988 and worked there through 2023 as a tenured Attending Physician. During this time at MSKCC, Dr. Chapman led many clinical and laboratory studies designed to develop new and improved treatments for melanoma. This included the first BRAF targeted therapy trial and several immunotherapy trials. His research continues to focus on developing new treatments for melanoma.

Board Certifications
American Board of Internal Medicine
American Board of Internal Medicine (Medical Oncology)
Clinical Expertise
  • M.D.
    Cornell University Medical College
  • A.B.
    Cornell University
  • Attending Physician
    Memorial Sloan-Kettering Cancer Center
  • Attending Physician
    NewYork-Presbyterian Hospital
  • Professor of Medicine
    Weill Cornell Medical College, Cornell University

Relationships and collaborations with for-profit and not-for profit organizations are of vital importance to our faculty because these exchanges of scientific information foster innovation. As experts in their fields, WCM physicians and scientists are sought after by many organizations to consult and educate. WCM and its faculty make this information available to the public, thus creating a transparent environment.

Pfizer, Inc.
Rgenix, Inc.